ClinicalTrials.gg
Not yet recruitingNCT07855016Updated Oct 2, 2026

A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma

A Phase 2 interventional study of TT-01488 Tablets and Rituximab in Mantle Cell Lymphoma (MCL), sponsored by TransThera Sciences (Nanjing), Inc.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by TransThera Sciences (Nanjing), Inc. · Phase 2, Interventional, and Treatment

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
188
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Lymphoma, Mantle-Cell with a site in China — 44 open to participants now, 56 under way, 10 of them phase 3. Lymphoma, Mantle-Cell · China.

Planned enrollment
18th of 91
188 · median 50
Started
2026
with 9 others
Phase 2
31 of 98
19 open now
Primary completion
2029-10
later than 45 of 55 live
Registered
98th of 98
by date

Among the 98 studies in Lymphoma, Mantle-Cell with a site in China, this one is the 18th largest by planned enrollment of the 91 interventional ones that give a count, is one of 10 that started in 2026, is one of 31 in phase 2, reaches primary completion later than 45 of the 55 other live ones, and was the 98th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

44 of the 98 studies in Lymphoma, Mantle-Cell with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Lymphoma, Mantle-Cell with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label, phase II study evaluating TT-01488 in combination with different anti-CD20 monoclonal antibody-containing regimens for the treatment of treatment-naïve mantle cell lymphoma (MCL).

Read the detailed description

The study comprises three combination treatment cohorts: Cohort A, TT-01488 plus rituximab; Cohort B, TT-01488 plus rituximab plus an immunomodulatory agent; and Cohort C, TT-01488 plus rituximab plus a BCL2 inhibitor. Each treatment cohort consists of two parts: dose exploration (Part A) and efficacy exploration (Part B). Cohort A will be initiated first. The Safety Monitoring Committee (SMC) will conduct a comprehensive review and assessment based on the safety data from Cohort A, incorporating all available pharmacokinetic (PK) and preliminary efficacy data. Based on the SMC's recommendations, the study team will determine the timing for sequential initiation of Cohorts B and C.

Part A of Cohort A uses a randomized, open-label design. Twelve patients with relapsed or refractory MCL will initially be enrolled and randomized 1:1 to two different TT-01488 tablet dose groups, receiving TT-01488 tablets plus rituximab 375 mg/m². Part B uses a Simon two-stage design, enrolling treatment-naïve MCL patients to receive TT-01488 at the recommended phase 2 dose (RP2D) plus rituximab 375 mg/m².

03

Conditions studied

  • Mantle Cell Lymphoma (MCL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Combination Cohort A: Part A (dose exploration): Age ≥18 years; no requirement for transplant ineligibility. Part B (efficacy exploration): Age ≥65 years, or 60 to \<65 years with ≥1 of the following criteria for stem cell transplantation (auto-SCT) ineligibility:① (LVEF) ≤45%;② (CrCl) 30-\<70 mL/min;③ diffusing capacity of the lung for carbon monoxide (DLCO) ≤60% predicted;④ performance status (ECOG PS) 2;⑤ cumulative illness rating scale (CIRS) total score >6;⑥ other comorbidities precluding intensive induction chemotherapy and transplantation, as assessed by the investigator;
  • Combination Cohorts B and C: Age ≥18 years;
  • confirmed MCL, CD20-positive, with documented high Cyclin D1 expression by immunohistochemistry (IHC) and/or positive t(11;14) by cytogenetics;
  • Ann Arbor clinical stage II-IV;
  • Part A (Dose exploration): ≥1 , disease, no prior BTK inhibitor, and ≤3 total prior lines.Part B (Efficacy exploration): No prior systemic therapy for MCL;
  • At least one ;
  • ECOG performance status 0-2;
  • Adequate organ function within 7 days before first dose;
  • Women of : negative pregnancy test before treatment and effective during the study and for 6 months after the last dose; male participants: effective contraception during the same period;
  • Written obtained before study participation.

Exclusion criteria

Exclusion Criteria:

  • Participants whose treatment intent is tumor debulking prior to stem cell transplantation;
  • Active central nervous system (CNS) involvement by lymphoma, , or history of spinal cord compression;
  • Severe cardiovascular disease within 6 months prior to screening;
  • Any active major infection (e.g., bacterial, viral, or fungal), including CMV DNA PCR-positive participants;
  • Serological evidence of active or infection;
  • Known history of (HIV) infection;
  • History of stroke or intracranial hemorrhage within 6 months before first dose of study drug;
  • History of bleeding diathesis (e.g., hemophilia, von Willebrand disease); requiring or currently receiving anticoagulation with warfarin or equivalent vitamin K antagonists;
  • Requires strong inhibitors or inducers. Strong CYP3A4 inhibitors within 1 week or strong CYP3A4 inducers within 3 weeks before first dose of study drug are prohibited;
  • Concurrent or prior , except adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in situ, or other cancers with no disease progression for ≥2 years;
  • Malabsorption syndrome or significant gastrointestinal dysfunction (e.g., gastrectomy, small bowel resection, symptomatic inflammatory bowel disease, complete/incomplete intestinal obstruction).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
188 participants (estimated)

Study arms

  • Experimental
    Combination Cohort A, Part A dose evaluation

    Combination dose evaluation and RP2D determination ; Two dose levels of TT-01488 to be evaluated; R/R MCL participants will be enrolled.

    Drug: TT-01488 Tablets · Drug: Rituximab

  • Experimental
    Combination Cohort A, Part B efficacy evaluation

    Participants with treatment-naive mantle cell lymphoma (MCL).

    Drug: TT-01488 Tablets · Drug: Rituximab

  • Experimental
    Combination Cohort B, Part A dose evaluation

    Combination dose evaluation and RP2D determination; R/R MCL participants will be enrolled.

    Drug: TT-01488 Tablets · Drug: Rituximab · Drug: Immunomodulatory Agent

  • Experimental
    Combination Cohort B, Part B efficacy evaluation

    Participants with treatment-naive mantle cell lymphoma (MCL).

    Drug: TT-01488 Tablets · Drug: Rituximab · Drug: Immunomodulatory Agent

  • Experimental
    Experimental: Combination Cohort C, Part A dose evaluation

    Combination dose evaluation and RP2D determination; R/R MCL participants will be enrolled.

    Drug: TT-01488 Tablets · Drug: Rituximab · Drug: BCL2 Inhibitor

  • Experimental
    Experimental: Combination Cohort C, Part B dose evaluation

    Participants with treatment-naive mantle cell lymphoma (MCL).

    Drug: TT-01488 Tablets · Drug: Rituximab · Drug: BCL2 Inhibitor

Interventions

06

What researchers measure

Primary outcomes

  1. Part A Dose-limiting toxicity (DLT)

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Part B Complete Response Rate (CRR) After 6 Cycles of Induction Therapy

    Time frame: After 6 cycles of induction therapy (each cycle is 28 days)

Secondary outcomes

  1. Part A Maximum Plasma Concentration (Cmax) of TT-01488

    Time frame: Up to 60 months

  2. Part A Time to Reach Maximum Plasma Concentration (Tmax) of TT-01488

    Time frame: Up to 60 months

  3. Part A Terminal Half-Life (t1/2) of TT-01488

    Time frame: Up to 60 months

  4. Part A Area Under the Plasma Concentration-Time Curve During the Dosing Interval (AUCtau) of TT-01488

    Time frame: Up to 60 months

  5. Part A Area Under the Plasma Concentration-Time Curve From Time 0 to Time t (AUC0-t) of TT-01488

    Time frame: Up to 60 months

  6. Part B Objective Response Rate (ORR) After 6 cycles of induction therapy

    Time frame: After 6 cycles of induction therapy (each cycle is 28 days)

  7. Part B Best Objective Response Rate (ORR) During Treatment

    Time frame: Up to 60 months

  8. Part B Best Complete Response Rate (CRR) During Treatment

    Time frame: Up to 60 months

  9. Part B Time to Response (TTR)

    Time frame: Up to 60 months

  10. Part B Duration of Response (DOR)

    Time frame: Up to 60 months

  11. Part B PFS rates at 12, 24, 36, 48, and 60 months

    Time frame: Up to 60 months

  12. Part B OS rates at 12, 24, 36, 48, and 60 months

    Time frame: Up to 60 months

  13. Part B Safety and Tolerability

    Time frame: Up to 60 months

  14. PartBChange From Baseline in EQ-5D-5L Utility Index Score

    Time frame: Up to 60 months

  15. Part B Change From Baseline in Global Health Status/Quality of Life Using the EORTC QLQ-C30

    Time frame: Up to 60 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2029, 36 months later.

Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 36 months is below that.

Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Oct 2, 2026
StartEst.
Oct 10, 2026
Primary completionEst.
Oct 10, 2029
CompletionEst.
Oct 10, 2029
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855016
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Oct 10, 2026 (estimated)
Primary completion
Oct 10, 2029 (estimated)
Completion
Oct 10, 2029 (estimated)
Last update
Oct 2, 2026

Study contacts

Caixia Sun
Contact
clinicaltrial@transtherabio.com
025-58216298

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BTK Inhibitor TT-01488

Start the discussion